New Jersey federal judge Freda Wolfson rejected Mylan‘s (NSDQ:MYL) request to move an antitrust lawsuit brought against the EpiPen maker to Kansas.
Mylan previously claimed that moving the case to Kansas would consolidate it with other class actions from EpiPen buyers – all of which are alleging violations of antitrust laws. Wolfson blocked the request without comment.
Get the full story at our sister site, Drug Delivery Business News.
The post Judge rules that Mylan can’t move EpiPen antitrust suit appeared first on MassDevice.